posted on 2020-02-04, 14:45authored byQi Mao, Bingjie Zhang, Wanwan Li, Sheng Tian, Wenqing Shui, Na Ye
The
5-HT2C receptor has emerged as a promising target
in the treatment of a variety of central nervous system disorders.
We have first identified aporphines as a new class of 5-HT2C receptor agonists. Structure–activity relationship results
indicate that the aporphine core may be required for 5-HT2C receptor activity, and substitutions at its C1 position are important
for 5-HT2C receptor activity. Our efforts to optimize our
hit 15781 lead to the identification of the highly potent
and selective 5-HT2C agonist 18b (MQ02-439) with an EC50 value of 104 nM and weak antagonism at
the 5-HT2A and 5-HT2B receptors. The findings
may serve as good starting points for the development of more potent
and selective 5-HT2C agonists as valuable pharmacological
tools or potential drug candidates.